Cost-Utility Analysis and Budget Impact Analysis of Eculizumab and Ravulizumab Compared to Plasmapheresis for Atypical Hemolytic Uremic Syndrome in Thailand
Cost-Utility Analysis and Budget Impact Analysis of Eculizumab and Ravulizumab Compared to Plasmapheresis for Atypical Hemolytic Uremic Syndrome in Thailand. // Kidney Medicine. – URL: https://www.sciencedirect.com/science/article/pii/S2590059526003705?dgcid=rss_sd_all
Cost-Utility Analysis and Budget Impact Analysis of Eculizumab and Ravulizumab Compared to Plasmapheresis for Atypical Hemolytic Uremic Syndrome in Thailand. Kidney Medicine. https://www.sciencedirect.com/science/article/pii/S2590059526003705?dgcid=rss_sd_all
“Cost-Utility Analysis and Budget Impact Analysis of Eculizumab and Ravulizumab Compared to Plasmapheresis for Atypical Hemolytic Uremic Syndrome in Thailand.” Kidney Medicine.
@article{article57615,
title = {Cost-Utility Analysis and Budget Impact Analysis of Eculizumab and Ravulizumab Compared to Plasmapheresis for Atypical Hemolytic Uremic Syndrome in Thailand},
journal = {Kidney Medicine},
url = {https://www.sciencedirect.com/science/article/pii/S2590059526003705?dgcid=rss_sd_all}
}
Abstract Background Macrophage polarisation plays a crucial role in sepsis‐associated inflammatory responses; however, the underlying molecular regulatory mechanisms remain to be further explored. Aim This study aimed to explore the...